Nordic pharmaceutical company Navamedic (Oslo: NAVA) announced on Wednesday that it has expanded its portfolio of antibiotics for hospital use, under an agreement with its partner InfoRLife SA, a subsidiary of ACS Dobfar S.p.A.

This agreement means that Navamedic has acquired the rights and marketing authorisations for Clindamycin ready-to-administer bags developed and manufactured by InfoRLife AS.

According to Navamedic, Clindamycin is an antibiotic used to treat severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract. This ready-to-use packaging provides benefits such as a reduction in medication errors, reduced risk of contamination, storage at ambient temperature and saving on nurse time, as well as a reduction of waste.

The company added that it already markets Clindamycin in traditional ampoules as part of the large portfolio of antibiotics acquired from ACS Dobfar in 2020.